Unknown

Dataset Information

0

Molecular Risk Stratification in Aggressive B-Cell Lymphomas.

ABSTRACT:

SUBMITTER: Frosch ZAK 

PROVIDER: S-EPMC7302956 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification.
| S-EPMC6720105 | biostudies-literature
Unknown Approaches to aggressive B-cell lymphomas in less fit patients.
| S-EPMC7727524 | biostudies-literature
Unknown Nonhepatosplenic ?? T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation.
| S-EPMC3136885 | biostudies-literature
Unknown Genetic background and evolution of relapses in aggressive B-cell lymphomas.
| S-EPMC5566014 | biostudies-literature
Proteomics Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas
2024-05-02 | PXD041891 | Pride
Unknown PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.
| S-EPMC6264635 | biostudies-literature
Unknown Novel therapies for relapsed/refractory aggressive lymphomas.
| S-EPMC6245978 | biostudies-literature
Unknown Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies.
| S-EPMC7854294 | biostudies-literature
Unknown Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.
| S-EPMC7115916 | biostudies-literature
Unknown Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas.
| S-EPMC7226002 | biostudies-literature